Venture Partners Ix Lp Morg... Net Worth

The estimated Net Worth of Venture Partners Ix Lp Morg... is at least $108 Thousand dollars as of 7 October 2014. Venture Morg owns over 350,000 units of Calithera Biosciences Inc stock worth over $108,096 and over the last 10 years Venture sold CALA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture Morg CALA stock SEC Form 4 insiders trading

Venture has made over 1 trades of the Calithera Biosciences Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Venture bought 350,000 units of CALA stock worth $3,500,000 on 7 October 2014.

The largest trade Venture's ever made was buying 350,000 units of Calithera Biosciences Inc stock on 7 October 2014 worth over $3,500,000. On average, Venture trades about 175,000 units every 0 days since 2014. As of 7 October 2014 Venture still owns at least 2,161,915 units of Calithera Biosciences Inc stock.

You can see the complete history of Venture Morg stock trades at the bottom of the page.

What's Venture Morg's mailing address?

Venture's mailing address filed with the SEC is 2710 SAND HILL ROAD, SUITE 100, , MENLO PARK, CA, 94025.

Insiders trading at Calithera Biosciences Inc

Over the last 10 years, insiders at Calithera Biosciences Inc have traded over $23,150,153 worth of Calithera Biosciences Inc stock and bought 7,859,025 units worth $49,155,939 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Partners Gp, L.L.C...., and Deepika Pakianathan. On average, Calithera Biosciences Inc executives and independent directors trade stock every 43 days with the average trade being worth of $8,053. The most recent stock trade was executed by Deepika Pakianathan on 27 January 2023, trading 121,333 units of CALA stock currently worth $47,320.

What does Calithera Biosciences Inc do?

calithera is focused on discovering and developing first-in-class small molecule drugs that slow tumor growth through controlling key metabolic pathways in the tumor and immune cells. tumor metabolism and tumor immunology are promising new interrelated fields for cancer drug discovery. recent clinical successes have demonstrated the potential to slow abnormal cell growth and create fundamentally new therapies for cancer patients. our investigational onco-metabolism medicines take advantage of the different metabolic requirements of tumor cells and cancer-fighting immune cells. calithera’s discovery and development efforts are focused on solid tumors for which new treatments are urgently needed. we are currently developing our lead candidate in phase 2 trials in patients with renal cell carcinoma, triple negative breast cancer. targeting cancer, differently. our onco-metabolism approach brings an enhanced perspective to cancer.

Complete history of Venture Morg stock trades at Calithera Biosciences Inc

Calithera Biosciences Inc executives and stock owners

Calithera Biosciences Inc executives and other stock owners filed with the SEC include:

• Susan Molineaux,
  President, Chief Executive Officer, Co-Founder, Director
• Sumita Ray,
  Senior Vice President, Chief Compliance Officer, General Counsel
• Keith Orford,
  Chief Medical Officer
• Curtis Hecht,
  Chief Business Officer
• Dr. Susan M. Molineaux Ph.D.,
  Founder, CEO, Pres & Director
• Christopher Molineaux,
  Senior Vice President - Development
• Eric Sjogren,
  Senior Vice President - Drug Discovery
• Deepa Pakianathan,
  Lead Independent Director
• H. Ward Wolff,
  Independent Director
• Jean George,
  Independent Director
• Sunil Agarwal,
  Independent Director
• Suzy Jones,
  Independent Director
• Blake Wise,
  Independent Director
• Jonathan Drachman,
  Independent Director
• Scott Garland,
  Independent Director
• Jennifer McNealey,
  Vice President, Investor Relations and Strategy
• Francesco Parlati,
  Vice President - Research
• Stephanie Wong,
  Vice President - Finance, Secretary
• Dr. Allison Dillon Ph.D.,
  Sr. VP of Commercial & Portfolio Strategy
• Dr. Susan B. Demo Ph.D.,
  Sr. VP of R&D Operations
• Matthew Gross,
  Head of Bus. Devel.
• Dr. Emil T. Kuriakose M.D.,
  Chief Medical Officer
• Frank Parlati,
  Sr. VP of Research
• Dr. Christopher J. Molineaux Ph.D.,
  Sr. VP of Devel.
• Dr. Eric B. Sjogren,
  Sr. VP of Drug Discovery
• Sumita Ray J.D.,
  Chief Legal & Admin. Officer
• Stephanie Wong,
  CFO & Sec.
• Capital Partners Gp, L.L.C....,
  
• William D. Waddill,
  SENIOR VP & CFO
• Mark K Bennett,
  SR. VP, RESEARCH
• Venture Partners Ix Lp Morg...,
  10% owner
• Management Partners Viii, L...,
  
• Technology Ventures Viii Lp...,
  
• Ralph E Christoffersen,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Pharmaceutical Co Ltd Taked...,
  
• Deepika Pakianathan,
  Director
• Emil Kuriakose,
  CHIEF MEDICAL OFFICER